Antibody responses in nasal secretions and serum of elderly persons following local or parenteral administration of inactivated influenza virus vaccine. 1969

J A Kasel, and E B Hume, and R V Fulk, and Y Togo, and M Huber, and R B Hornick

UI MeSH Term Description Entries
D007252 Influenza Vaccines Vaccines used to prevent infection by viruses in the family ORTHOMYXOVIRIDAE. It includes both killed and attenuated vaccines. The composition of the vaccines is changed each year in response to antigenic shifts and changes in prevalence of influenza virus strains. The flu vaccines may be mono- or multi-valent, which contains one or more ALPHAINFLUENZAVIRUS and BETAINFLUENZAVIRUS strains. Flu Vaccine,Influenzavirus Vaccine,Monovalent Influenza Vaccine,Universal Flu Vaccine,Universal Influenza Vaccine,Flu Vaccines,High-Dose Trivalent Influenza Vaccine,Influenza Vaccine,Influenza Virus Vaccine,Influenza Virus Vaccines,Influenzavirus Vaccines,Intranasal Live-Attenuated Influenza Vaccine,LAIV Vaccine,Monovalent Influenza Vaccines,Quadrivalent Influenza Vaccine,Trivalent Influenza Vaccine,Trivalent Live Attenuated Influenza Vaccine,Universal Flu Vaccines,Universal Influenza Vaccines,Flu Vaccine, Universal,High Dose Trivalent Influenza Vaccine,Influenza Vaccine, Monovalent,Influenza Vaccine, Quadrivalent,Influenza Vaccine, Trivalent,Influenza Vaccine, Universal,Intranasal Live Attenuated Influenza Vaccine,Vaccine, Flu,Vaccine, Influenza,Vaccine, Influenza Virus,Vaccine, Influenzavirus,Vaccine, LAIV,Vaccine, Monovalent Influenza,Vaccine, Quadrivalent Influenza,Vaccine, Trivalent Influenza,Virus Vaccine, Influenza
D007279 Injections, Subcutaneous Forceful administration under the skin of liquid medication, nutrient, or other fluid through a hollow needle piercing the skin. Subcutaneous Injections,Injection, Subcutaneous,Subcutaneous Injection
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009093 Mucus The viscous secretion of mucous membranes. It contains mucin, white blood cells, water, inorganic salts, and exfoliated cells.
D009500 Neutralization Tests The measurement of infection-blocking titer of ANTISERA by testing a series of dilutions for a given virus-antiserum interaction end-point, which is generally the dilution at which tissue cultures inoculated with the serum-virus mixtures demonstrate cytopathology (CPE) or the dilution at which 50% of test animals injected with serum-virus mixtures show infectivity (ID50) or die (LD50). Neutralization Test,Test, Neutralization,Tests, Neutralization
D011233 Precipitin Tests Serologic tests in which a positive reaction manifested by visible CHEMICAL PRECIPITATION occurs when a soluble ANTIGEN reacts with its precipitins, i.e., ANTIBODIES that can form a precipitate. Precipitin Test,Test, Precipitin,Tests, Precipitin
D006383 Hemadsorption Inhibition Tests Serological tests that measure anti-hemadsorption agents such as antiviral ANTIBODIES that block VIRAL HEMAGGLUNININS from adhering to the surface of red blood cells. Hemadsorption Inhibition Test,Inhibition Test, Hemadsorption,Inhibition Tests, Hemadsorption,Test, Hemadsorption Inhibition,Tests, Hemadsorption Inhibition
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000336 Aerosols Colloids with a gaseous dispersing phase and either liquid (fog) or solid (smoke) dispersed phase; used in fumigation or in inhalation therapy; may contain propellant agents. Aerosol

Related Publications

J A Kasel, and E B Hume, and R V Fulk, and Y Togo, and M Huber, and R B Hornick
April 1969, Journal of immunology (Baltimore, Md. : 1950),
J A Kasel, and E B Hume, and R V Fulk, and Y Togo, and M Huber, and R B Hornick
September 1971, Journal of immunology (Baltimore, Md. : 1950),
J A Kasel, and E B Hume, and R V Fulk, and Y Togo, and M Huber, and R B Hornick
January 1986, International archives of allergy and applied immunology,
J A Kasel, and E B Hume, and R V Fulk, and Y Togo, and M Huber, and R B Hornick
January 1970, Journal of immunology (Baltimore, Md. : 1950),
J A Kasel, and E B Hume, and R V Fulk, and Y Togo, and M Huber, and R B Hornick
December 1989, Journal of clinical microbiology,
J A Kasel, and E B Hume, and R V Fulk, and Y Togo, and M Huber, and R B Hornick
February 2000, Vaccine,
J A Kasel, and E B Hume, and R V Fulk, and Y Togo, and M Huber, and R B Hornick
September 1996, Clinical and diagnostic laboratory immunology,
J A Kasel, and E B Hume, and R V Fulk, and Y Togo, and M Huber, and R B Hornick
October 1973, JAMA,
J A Kasel, and E B Hume, and R V Fulk, and Y Togo, and M Huber, and R B Hornick
March 1969, The New England journal of medicine,
Copied contents to your clipboard!